[BidClub_]
Sourcery · · 60 分钟

拯救人类竞速:走进120亿美元 Colossal Biosciences与38亿美元 Astromech

Ben LammMolly O'Shea

YouTube
TL;DR
  • Colossal 的猛犸鼠是全流程能力的验证,而不是公关噱头——100%健康出生的小鼠全部呈现预测中的表型,携带“单次递送的多重编辑数量创纪录”,并在30天内完成工程改造。 Lamm对此最不满的是,在围绕可爱的讨论中,“30天”这一点被忽略了;真正的意义在于:在妊娠期21–22天的动物身上验证针对猛犸象的编辑目标,而不是拿一头濒危、妊娠期22个月的大象做测试。
  • Colossal累计融资6.35亿美元,最近一轮原定2亿美元、最终获4亿美元超额认购,且每轮超额认购都超过2倍。 Lamm的判断是:“我们把每一轮的定价都完全定错了……我们太便宜、太容易拿下资金,应该提高资本价格”,并称Colossal是“全球估值最低的公司之一”,因为公司有能力“在行星尺度上保护、工程化改造并引导生命”。
  • Colossal的商业模式不是卖动物;Molly将更广阔的机会概括为“文明科技”(civilization tech),Lamm则描述了政府级应用:针对入侵物种的基因驱动(全球“5000亿美元级问题”)、人工子宫,以及人类健康应用。 螺旋蝇案例最能说明这笔账:纳税人正在用8年约15亿美元来遏制问题,而Colossal已经做出的方案“在我们做过的每个模型中,都可能在6到7个月内彻底消除整个问题”——前提是拿到公司目前尚未取得的政府许可。
  • 分拆公司 Astromec 最近完成融资(“眼下近期可能还在、也可能没有在募资”),利用聚焦型进化基因组学 AI 做药物发现——“我们不需要去建一座5000亿美元的数据中心”。 其机制在于:大象通过p53过度表达,将癌症发生率控制在2–3%,而人类为24–25%;Colossal掌握全球最大的大象数据集和多物种疱疹病毒数据集,可据此训练预测模型,应用于癌症演化和禽流感等领域。
  • 本期对物种灭绝的铺垫是:未来25年生物多样性最多可能损失50%,而Lamm表示,保护行动“根本跟不上物种被灭绝的速度”。 他对批评者的回应是,去灭绝属于“新增资金、新增技术”,不是替代方案;所有技术都免费开源给保护项目使用。他还反问:“你难道不愿意拥有一套去灭绝工具包、最后用不上它,也不愿意在需要时发现手里没有吗?”
  • Lamm最激进的判断是,AI最终会汇聚成“自然的数字孪生”(a digital twin of nature)——像导弹防御和海啸预警那样进行实时预测,展示每座数据中心或每条改道河流对生态系统的后果。 他称这会“带来极大启发,同时也可怕得令人胆寒”,并认为它能让人类把已经工程化生产的物种投入使用,以抵消人类决策带来的负面影响。
  • 编辑能力的提升速度已经超过原先承诺,下一个里程碑已被预告但尚未命名。 投资人曾认为,5年内完成5–7处编辑就已经很出色;Lamm称Colossal现在已经能做100处编辑,同时又在其他场合说是“数百处”,并正在推进一种新构造和递送机制,以实现一次完成数千处编辑。未来12个月内,他最期待的是“Colossal可能让下一个灭绝物种诞生”——至于是哪一种,“我不说”。
摘要 · 为研究而整理的核心内容

1. 猛犸鼠是端到端流水线演示——30天比可爱更重要

  • Lamm在镜头前展示的 Gen 2 小鼠,是最初那批小鼠的后代;它们是“继我们的恐狼之后,地球上基因改造程度第二高的多细胞生物”。他对发布报道的核心不满是:“我们让100%健康的小鼠出生,全部呈现预测中的表型,单次递送的多重编辑数量创下历史纪录,而且只用了30天……但30天这一点被忽略了。”
  • 这项小鼠实验的逻辑在于:大象妊娠期22个月且属于濒危物种,因此Colossal先找出与猛犸象编辑对应的小鼠基因,再在妊娠期21–22天的动物身上验证表型预测。“这证明我们的端到端流水线跑通了。”
  • 后续发展近乎超现实:超级粉丝跑到非公开办公室,“合法化猛犸鼠” Etsy T恤大卖——“这很奇怪,因为它们并不违法”;与CRISPR婴儿事件有关的中国科学家发帖称这些小鼠是生物武器;Molly还讲到,Smithsonian曾要求等小鼠死亡后把它们制成剥制标本。对于买家提出的购买请求,Lamm的回答是:“我们不做卖动物的生意。”

2. 累计融资6.35亿美元,每轮超额认购2倍以上——建立在Lamm承认自己会放弃的一份融资材料之上

  • 最近一轮原定融资2亿美元,最终获得4亿美元认购;Colossal累计融资6.35亿美元,而且“我们才刚刚开始。我相信还会继续融到更多资本”。每轮超额认购都超过2倍,因此Lamm说:“我从中听到的是,我们太便宜了……我们太容易拿下资金,应该提高资本价格。”
  • 投资人筛选是有意为之:公司选择了Jim Breyer、Thomas Tull和Mark Walter等长周期技术与影响力投资人,而不是要求“4到5年实现基金回报”的资金;公司最初考虑过Masa/SoftBank路线,但最终没有采用。投资人从第一天起就必须接受,“启发性需要和创造价值同等重要”。
  • Lamm坦率回顾公司的起点:最初的融资材料写的是,“我们没有科学家,没有和Harvard的合作关系,也没有任何技术……George Church认为自己能造出一头猛犸象”。他的结论是:“我本来会放弃这个项目。说真的,我绝对会放弃。”真正改变局面的是通过不断设定并超越预期建立信任,其中恐狼项目成为标志性的“惊喜时刻”。

3. 真正的生意:基因驱动、人工子宫,以及Colossal此前没意识到的需求

  • Molly提出“文明科技”这一概念;Lamm将其解释为一类影响范围超出直接产品或服务的技术。仅入侵物种就是一个“全球5000亿美元级问题”:岛上的老鼠、得州的螺旋蝇,以及传播莱姆病、危害美国东北部麋鹿和鹿的蜱虫。如今的替代方案,是喷洒会毒害生态系统的化学品。
  • 源源不断的主动需求仍在让Lamm感到意外:一家每年采购价值数十亿美元、来源符合伦理规范的动物纤维的买方,希望Colossal把本土供应量提高到5倍;实现方式可能是克隆,也可能是Colossal已经展示过的实验室培育路线——用大象干细胞培育猛犸象毛囊,“一盘又一盘,整座仓库”,全程甚至不必接触动物。与此同时,中东方面的相关利益方希望复育一种已经灭绝或接近灭绝的鸟类,以及一种极度濒危的鸟类;此前人工鸟蛋项目已经投入数十亿美元,却没有成功。
  • Lamm称Colossal在人类健康的相邻领域也处于领先位置,包括用于IVF和胚胎健康的人工子宫组件,以及通过生殖系编辑处理遗传疾病状态——“Colossal是这方面的全球领导者”。他点名的风险是:“必须确保我们专注于核心使命,不要因为这些巨大的经济机会而偏离太远。”

4. Astromec:从进化趋势中发现药物,而不是靠蛮力堆算力

  • 分拆公司 Astromec “最近完成了融资,眼下近期可能还在、也可能没有在募资”,定位刻意保持狭窄:公司“不需要去建一座5000亿美元的数据中心……也不需要争夺水资源”。它关注的是,为什么进化会在不同物种间保留某些基因组区域。
  • 最典型的案例是大象p53过度表达:大象癌症发生率为2–3%,人类则为24–25%。Colossal掌握全球最大的大象数据集,以及全球最大的多物种疱疹病毒数据集;其中EEHV会杀死大象。这些数据将用于构建预测模型,“不仅适用于癌症演化,也适用于禽流感等问题”。
  • Lamm对AI与生物科技融合的宏观判断是:“你会看到一场前寒武纪式的新药和新疗法大爆发,所有这些都来自AI辅助的药物设计和发现。”

5. 黑暗的计算:25年内生物多样性损失50%,以及反驳保护主义者的工具包逻辑

  • Molly抛出的统计是:“目前的预测是,未来25年我们将失去全部生物多样性的最多50%。”Lamm认为这个数字既黑暗又带有希望:“所以我们必须做点什么。”他表示,这不是保护行动是否应被替代的问题——“无论保护做得多好,都根本跟不上物种被灭绝的速度。”
  • 保护界过去一直是最公开、最强烈的批评者之一;相关反馈已经从“负面变成中性”,如今正变得更加积极。Lamm的反驳是,问人类是否正在赢得拯救物种的战斗,保护主义者“都会告诉你,不是”。Colossal带来的是“全新的想法、全新的资金、全新的技术”;所有技术都免费开源给保护项目使用,大象保护合作方也会告诉你,“自Colossal成立以来,他们获得的资金增加了”。
  • 这套标志性的表述还带有《Star Trek》中蓝鲸穿越时空的桥段:“你难道不愿意拥有一套去灭绝工具包、最后用不上它,也不愿意在需要时发现手里没有吗?”尤其是因为“我们知道自己正身处”一场大规模灭绝事件之中。至于技术被滥用,坏人不可避免,但“这不意味着我们不应为了正面应用场景而创新这些技术”。
  • Lamm最激进的判断将所有问题串联起来:人类最终会建立“自然的数字孪生”——像导弹防御或海啸预警系统那样,但服务于生态系统,让我们理解灭绝一个物种或“建设XYZ数据中心”会对水质、粮食安全和人畜共患病产生什么连锁影响。“这会带来极大启发,同时也可怕得令人胆寒。”

6. 再野化是真实目标,但受政府许可约束——螺旋蝇说明了问题的利害

  • 所有项目——灭绝物种、基因驱动和克隆濒危动物——最终都计划回归野外,但前提是政府、原住民群体和私人土地所有者达成一致:“他们必须给我们绿灯。”Colossal目前正在向美国农业部、情报界和战争部介绍这项技术。
  • 在Bluesky上的批评者指出Colossal没有许可后,螺旋蝇的账算得更清楚了:“是的,我们没有许可,但是……”政府正在用8年15亿美元的纳税人资金,减缓或阻止一个威胁得州养牛业的问题;而Colossal已经做出的方案“在我们做过的每个模型中,都可能在6到7个月内彻底消除整个问题”——既能缓解牛肉价格压力、减少动物痛苦,也能节省纳税人资金,同时无需喷洒化学品。
  • 未来12个月里,Lamm最期待的是“Colossal可能让下一个灭绝物种诞生”。至于是哪一种?“我不说。”

7. 组织设计:买下整条链条,再重新编程科学家

  • Lamm自嘲地说:“我毫无生物学和生物科技背景,反而再适合不过来经营这家公司。”这句话背后是一套从第一性原理出发的纵向整合逻辑:既然“灭绝是一个系统模型”,Colossal就自建、授权或收购整条供应链。收购ViaGen是典型案例:其克隆效率达到80%,而大多数人的水平只有2%。
  • 公司目前拥有260多人、17个学术合作方,以及80名在由Colossal资助的学术实验室工作的人;此外还有约95名分级顾问,覆盖科学、原住民事务、高管和青年顾问委员会。设置青年顾问委员会,是因为孩子“也将继承我们的解决方案”,而Lamm不想把他所谓“愚蠢”的直接空气捕集碳基础设施那种“技术债务”留给他们。
  • AI技术栈必须定制开发:“结果发现,Opus做不了基因组的祖先状态重建。”定制激光和克隆硬件配合持续录屏、计算机视觉,用于追踪效率,最终将通过机器人实现全面自动化。Lamm说:“我们做过最难的事,不是重新编程干细胞,而是重新编程科学家”,让他们使用Jira和Smartsheet;如今这些数据已经通过AI层汇总,实现接近实时的实验室可视化。

8. “Harvard遇上MTV”、禁区清单,以及把红杉编程成房子

  • 品牌从第一天起就建立在这种组合上:老派TRL时代的MTV气质,叠加Harvard的科学严谨性。“如果我说是Harvard遇上MTV,你会觉得,这说法太蠢了。但……这确实精准描述了你们造出来的东西。”这也是招聘武器:“在这里工作之后再回学术界吧……你们的实验室现在还靠披萨盒子撑着。”
  • 边界十分明确:公司内部不开展人类相关工作,但相关技术可以分拆出去并授权;也不对非人灵长类开展体内实验。Lamm说有人问过尼安德特人,但没有单独展开回答这个问题。巨猿“看起来会很惊艳,但我们不会去做”。他还表示不存在巨齿鲨DNA,尽管恐龙和巨齿鲨分别是排名第1和第2的需求;他直接否认了那些适合阴谋论的说法:没有秘密猛犸象,也没有外星人推动基因组工程的突破——“纯粹是疯话”。
  • Lamm与George Church共享一套跨度极长、怪异到“连Adam Draper都觉得过于离谱”的愿景:合成生物学最终将能够直接编程生命本身——“能不能造出一棵以房屋形态生长的红杉?”他对这个领域的总结是:“我认为我们推进它的程度超过了任何人,但与此同时,我们甚至还没有触及表面。”
Molly O'Shea

It’s currently forecast that we’re going to lose up to 50% of all biodiversity in the next 25 years. So that’s dark.

Ben Lamm

These are some of our woolly mice.

Molly O'Shea

Woolly mouse. Colossus woolly mouse. They’ve begun an experiment in their plan to revive the woolly mammoth.

Ben Lamm

It’s a good mouse. And the way the world is right now, let us have this.

We had 100% healthy mice born with exactly the predicted phenotypes, with the most multiplex edits delivered at one time ever, and we did it in 30 days.

Molly O'Shea

So, the last one was $400 million. You’ve raised $630 million in total.

Ben Lamm

Yeah, $635 million total. The last round was supposed to be $200 million, and it got oversubscribed to $400 million. We’re just getting started. I’m sure we’ll raise more capital.

One of our companies that we spun out is called Astromec. It’s using AI to build—it’s a very focused model. We do get requests for a megalodon quite a bit. We’re not working on that. There’s no secret U.S. Navy–Anduril mashup.

1. Inside Colossal's De-Extinction Lab

Molly O'Shea

Ben Lamm, welcome to Sorcery.

Ben Lamm

Welcome to Colossal.

Molly O'Shea

Thank you. This place is insane.

Ben Lamm

Yeah, it’s funny. Just wait until you go through the tour—it gets crazier.

Molly O'Shea

We have something pretty nuts over here. Do you want to show us what’s going on?

Ben Lamm

So, believe it or not, we do not have 330-pound, massive, extinct Pleistocene wolves here. So, we built an animatronic of one, and that actually is the size of Reheis, probably the most famous of our dire wolves. He was on the cover of Time.

We constantly have footage from the last 6 months that we project here. We thought that most people, when they come here, want to see them. They’re like, “Oh, can we see the dire wolves?” We’re like, “We’re in Texas. Where do you think we have them? You’re in an office building, right?”

So much of what we do is around inspiration and kids, because value creation, impact, and inspiration are our big core values that we try to think through in all of our decisions. Even thinking about trophic downgrading and the cascading effect that happens with wolves—the reintroduction of wolves into Yellowstone and what that looks like, and why predators are important—we’ve tried to think about, with our long-term museum partners, how we start to educate the public on the importance of keystone species, and specifically predators.

This is our dire wolf installation. We can thank Wētā Workshop from New Zealand. If you’re a fan of Peter Jackson, you’ll know those guys. And, yeah, that’s actually Romulus chewing on something disgusting. I don’t know if every single office you’ve been to has animatronic dire wolves.

Molly O'Shea

No, I have not seen any animatronics.

Ben Lamm

I’m sure there’ll be some crazy conspiracy based on that: “All the dire wolves are robots. They’re really a robotics company.” We get lots of interesting feedback.

Molly O'Shea

I have confirmed, after going into the avian lab, that the birds are real.

Ben Lamm

Yeah, birds are real. And the stuff we’re doing is real, so it’s kind of fun.

Molly O'Shea

Okay, so you want to show us around what you have in the lobby area, and then you can explain what’s behind the closed doors?

Ben Lamm

This is 55,000 square feet. We have another 30,000 square feet of lab space. Everything wraps around the lab, which you’re going to get to go deep in, which is exciting. All the offices, conference rooms, everything—all of our AI teams—wrap around the lab because the science is the heart of what we do here.

This was also made by Wētā. Most people think this is what we do, but as you spend time in the lab, you’ll see it’s way weirder, grosser, and more technical. Most people ask, “Why don’t you have a mammoth? Why don’t you have a dinosaur? Why can’t you just take frozen core samples and clone them?” But those tissues are dead. You cannot clone from dead cells.

We put this here because this is what most people think we do. When we launched, every cover was something like this—a mammoth preserved in ice. Just so you know, they look nothing like this, really. They’re disgusting, and the smell is awful. Even the permafrost—you can’t get it out of your pores forever.

Molly O'Shea

Yeah, so I’ve spent a bunch of time up in Alaska, in the permafrost caves in northern Alaska, in the Arctic Circle, and it’s just—I mean, it just gets in you, and it’s disgusting.

Ben Lamm

Really?

Molly O'Shea

Yeah.

Ben Lamm

Yeah. But you could just pretend it looks like that, and it smells like this, and it’s incredible. It does have its own signature scent.

I think we have the coolest streetwear that no one can get. It’s science streetwear. It’s super awesome.

Molly O'Shea

Everybody’s wearing it, too. You guys have great merch.

Ben Lamm

Yeah, but we don’t sell it. It’s only available to our employees and our favorite guests. We want to provide the greatest apparel. It’s not swag; it is apparel.

2. Every wall in this lab has a purpose

Everything that you see, when you go into the lab, is designed to provide all of these different educational moments that talk about our core values or explain something specific to that unique lab. We have a core lab that’s an open lab, and then we have individual labs off the core lab. This is one of our production labs and whatnot.

Sharing our core values and reminding people what they do is great, but the other thing we’ve done is try to pick technologies that are useful. On the other side—and you’ll see this in the lab—you actually can’t see any of this. This is one-way projection. It’s not a projector; it’s actually one-way nanofilm.

So, we can see it, but it’s not distracting. When you’re going to lunch, going to a meeting, or going to the bathroom, you’re consistently reminded of the things that matter and the things that we take pride in. But when you’re working in the lab, it’s not distracting.

3. The AI idea that could save the planet

Molly O'Shea

Ben, I have to ask you: What is your hottest take right now?

Ben Lamm

My hottest take right now is that I think AI is going to converge, and we are going to build a digital twin of nature. Just like we have prediction models for everything from missile defense to tsunamis and earthquakes, we’re going to have that for nature, and we’re going to understand in real time how nature is affected by every decision that we make. That’s going to be incredibly enlightening and terrifyingly scary.

But I think we’re going to build a digital twin of nature as humanity, where we will be able to truly understand the consequences of our decisions. Then we’ll be able to leverage technologies like what we have to productionize species to combat some of the adverse effects of those decisions.

Molly O'Shea

So why is that so important? You study de-extinction.

Ben Lamm

It’s so important to me because, ultimately, we don’t really know how everything works. We as humanity are like, “Oh, when people get locked in their houses for COVID, all of a sudden there are dolphins back in Italy.” But it’s like, why?

For us, thinking through and understanding the ramifications of that—thinking through how that affects things like water purity and scarcity and food security—all of these things are directly impacted by the ecosystem, and that’s also driven by the flora and fauna that are there.

If we don’t understand the ripple effects of either eradicating a species, building an XYZ data center, or diverting a river, then we don’t understand what that means to us, even in terms of our survivability in the face of a new zoonotic disease that arises, or food and water security.

4. What Colossal is building next

I think understanding a digital twin of nature, so that we can pick and choose the trade-offs as a society, is going to be critical to our long-term success. I see a world where all these systems, including AI, actually make it so that we’re better aligned with nature.

Molly O'Shea

What are you looking forward to most in the next 12 months?

Ben Lamm

The next 12 months? I’m looking forward to Colossal potentially having the next extinct species birthed.

Molly O'Shea

What is that going to be?

Ben Lamm

I’m not saying.

Molly O'Shea

Okay. To be continued.

Ben Lamm

To be continued.

Molly O'Shea

Thank you, Ben.

Ben Lamm

Yeah, thank you.

5. Revealing Colossal's woolly mice

Molly O'Shea

Okay, Ben, we just came from the lobby, I guess. We have something special in the room with us today. We actually have something in the room with us.

Ben Lamm

Yes.

Molly O'Shea

So, what are we about to reveal under the curtain?

Ben Lamm

Yes. These are some of our woolly mice. These are some of our Gen 2 mice from our successful woolly mouse project, which I think is objectively the cutest mouse on the planet. These are offspring from that first generation.

They’re probably not as famous as Chip and Dale were, but their offspring are, as you’re going to see, objectively as cute. These are the second-most genetically modified multicellular organisms on the planet, after our dire wolves. Do you want to take it off?

Molly O'Shea

Let’s do it.

Ben Lamm

Thank you.

Molly O'Shea

Oh my God.

Ben Lamm

Yeah, so, like I said, objectively pretty cute.

These mice, along our process to bring back the mammoth—you know, it takes 22 months to gestate an elephant, and elephants are endangered—you want to be very thoughtful in that whole process. With these mice, what’s great about 21- to 22-day gestation is that you can actually test a lot of those core phenotypes, or physical attributes, in the editing.

What was great about the first generation of the mice is that we made them in 30 days. That got lost in the shuffle, which blew me away. We had 100% healthy mice born with exactly the predicted phenotypes, with the most multiplex edits delivered at one time ever. And we did it in 30 days.

The 30-day part got lost when we announced the woolly mice because everyone was just talking about how objectively cute they were. But nobody really realized that it was all done in 30 days, which is amazing, right? We took all of these edits that we had been identifying for the woolly mammoth, identified the mouse equivalent of those, and then engineered them in 30 days and birthed mice, right? That’s crazy.

It showed that our end-to-end pipeline worked. It broke the internet. A bunch of people talked about it online and talked about how cute they were, and it was a testament to the fact that the prediction of the exact edits in the mouse equivalent of those edits worked, which was amazing.

6. Wild requests they get every day

Molly O'Shea

That’s crazy. And so I heard you guys have some super fans now. You have to keep everything under lock and key.

Ben Lamm

Yeah.

Molly O'Shea

Did you expect that?

Ben Lamm

So, our offices aren’t open to the general public, but we had people who just showed up very excited about the mice, which then made us even more concerned about the dire wolves. As you know, we don’t have dire wolves physically here, because you would have seen them.

Molly O'Shea

There’s one in the lobby.

Ben Lamm

An animatronic one, right? Because people come and they’re like, “But where are they?” That’s why we have that huge, 60-foot screen showing very early footage. We’re probably actually going to make that screen a real-time feed so you can just see them in real time.

Until we had the camera system working in high definition, we were just putting that loop on. Then we have the animatronic up there so people could at least see the scale and the size, and we wanted to make something that was Instagrammable when people showed up, right?

Having giant, 130-pound Pleistocene wolves in our Texas offices was probably a bad idea, but these guys obviously can fit much, much better here. Then we have an 8,000-square-foot vivarium that they all live in day to day.

It is exciting, and people got very excited about the woolly mice. We had to nicely remind people that we are not open to the general public, so you have to see everything on YouTube or the podcast. We don’t invite people in often.

Molly O'Shea

And people have—I’m sure you’ve gotten many requests for people to buy them.

Ben Lamm

Oh, we get a request every day. There were people who actually made “legalized woolly mice” T-shirts on Etsy, which is weird because they’re not illegal. And then the crazy scientist in China who did the CRISPR babies posted that they were bioweapons.

Molly O'Shea

What?

Ben Lamm

I know. We got so many crazy things. We had people who bought woolly mice pillows, and all kinds of bootleg, crazy rip-off products came out of it. Even the Smithsonian reached out to us and said, “Hey, look—”

Molly O'Shea

They’re mice. Eventually, they’re going to die. Could we—I mean, they were being realistic, because mice don’t have 40-year lifespans, right? They were like, “Could we taxidermy them and put them on display when they die?”

Ben Lamm

If you go to the Smithsonian National Museum of Natural History, you actually have that. We’ve had a lot of weird requests, but we do get schools, museums, and a lot of people asking to see them and asking us to donate them and take care of them.

We’re not in the selling-animals business, so it’s not currently a part of our roadmap.

Molly O'Shea

Are you going to give them to the Smithsonian?

Ben Lamm

I don’t know. We haven’t made any formal commitments.

7. Colossal's business model

Molly O'Shea

So, if selling animals is not the business model, what is the business model? I mean, the technology in these guys, I would argue, is probably the most revolutionary technology ever. There’s a new term—we were in an article recently—and we did not invent this, but there’s a new term called civilization tech. Have you heard this, or civ tech?

Ben Lamm

Yeah. It’s, like, I think the hot new thing.

Molly O'Shea

You create a new category.

Ben Lamm

No, no, we did not. We’re not—we’re in it, right? Anthropic was in it. I think it’s the evolution of the moonshot category, right? Now that Elon is going to put a whole base on the moon and then Mars, I guess we can’t call moonshots moonshots anymore.

I think this is a new category of technologies that have an application broader than their services or products for the market, but have a bigger ripple effect on tech, on humanity. I think genome engineering at scale, full DNA synthesis at scale, and artificial wombs at scale have an application that’s insane.

When we were at the conference where we met, we had just done our capital raise, our last capital round, and people were like, “Yeah, this is a very big round for a company this early.” They made some comment, and I said, “Yeah, I do think that we are one of the most undervalued companies in the world,” because I truly do.

8. How Colossal raised $635 million

The ability to preserve, engineer, and direct life on a planetary scale, in all species, I think is a pretty important skill set for humanity.

Molly O'Shea

That’s a really interesting point, though, on the size of your fundraises. The last one was $400 million. You’ve raised $635 million in total.

Ben Lamm

Yeah, $635 million total. The last round was supposed to be $200 million, and it got oversubscribed to $400 million.

Molly O'Shea

Not bad.

Ben Lamm

Yeah, yeah, yeah. And we’re just getting started. I’m sure we’ll raise more capital.

Molly O'Shea

On that point, though, I was listening to a few of your podcasts ahead of this that you’ve done. You’ve done so many great ones, but what I think is underrated is what you use that capital for. It’s not just the lab, but it’s the preserve, it’s the reserve—

Ben Lamm

Yeah. A lot of it goes into the halo effect of it. The effects are amazing. What’s interesting is we don’t know what we don’t know, even about the business model.

We know for a fact that there are government use cases around preserving life and building applications to different problem sets, like invasive species. Invasive species is a half-trillion-dollar problem globally. It’s huge, right?

Think about rats on islands. Think about the screwworm here in Texas, which is going to decimate the cattle industry. It’s terrible. It’s awful. Our choices are that beef prices go through the roof, we inoculate our cows—which a lot of people don’t want to do—or we attack the invasive species.

The best way to do that is a gene drive. It’s engineering in a safe protocol that then goes through the population and makes them sterile so that there are no future generations. If you are an animal-welfare person around insects, which is great—there are those people—this is a good solution for you, because we’re not out there spraying.

Right now, people are spraying chemicals. It’s very, very bad. The same thing is happening with Lyme disease and ticks in the Northeast, right? People are literally poisoning the environment and poisoning other animals and plants to get rid of ticks because of all the negative effects. It’s killing the moose population. It’s killing deer. It’s affecting people with Lyme disease.

There are all these huge problems around invasive species that we as humans cause. Using gene drives in biocontrol and biocontainment technologies to do that is hundreds of billions of dollars, right? Most people don’t realize that when they think about de-extinction.

Also, the technologies that we’re developing that have applications to human health care are insane, whether it’s individual pieces of the artificial womb for IVF and embryo health, or even going as far as being able to germline-edit out certain disease states for genetic diseases and disorders. Colossal is the world leader in that.

Those are things that we know, but we didn’t even know that 3 years ago. In the last few years, or a few months, we’ve had people come to us. There’s a particular type of fabric that comes from a particular type of animal that’s ethically harvested, but they literally buy billions of dollars’ worth of it from this country.

They came to us and said, “Hey, look, we need to increase this by 6×, and there’s just not enough of these animals, right? We’re going to keep buying from this, but how do we also do 5× more here domestically?”

We own the rights to the animals. Can we clone these animals? Can we even productionize it where it’s like lab-grown meat? I don’t know if you saw this in the lab, but we actually have hair follicles growing, and we’ve taken elephant stem cells and created follicles so that we can grow mammoth hair.

What if you did plates and plates of that and full warehouses of growing this without even touching the animals, right? It’s like the lab-grown equivalent of hair, which is kind of weird and cool. We’re the only company to do that, and they are buying billions of dollars’ worth of this and want to 5× it, and there’s just not that much available.

About 3 months ago, we didn't know about that, and now we're working on coming up with a solution to help them solve that. We've also had an extinct bird, or semi-extinct bird, and a critically endangered bird that a lot of the Middle East wants to help bring back because it's important to their falconry and culture. So they've come to us and said, “Look, this is billions of dollars in terms of research and conservation that we've spent, and we just haven't been successful with our artificial eggs and other technologies. We could help productionize that,” right?

These are the types of use cases that, once people understand the capability sets of artificial wombs for mammals and avians, all the way through genome engineering and computational analysis, create all these unique opportunities where people say, “Could you solve my problem with biology or genome engineering or artificial limbs?” And so the plethora of opportunities we have is interesting. I think the hardest thing that we will continue to have is making sure that we stay focused on our core mission and don't deviate too much for some of these large economic opportunities.

9. How AI is converging with Biotech

Molly O'Shea

I'm sure you're going to get inundated with more, especially because of AI. We haven't done many biotech interviews, but now, because AI is really converging with biotech, it's exploding.

Ben Lamm

It is truly exploding, right? You're going to see this pre-Cambrian explosion of new drugs and new therapies that all come from AI-assisted drug design and discovery. One of our companies that we spun out, called Astromec, which raised money recently and may or may not be raising money now, soonish—this is going to sound crazy—is a different way of looking at drugs. It's using AI to build a very focused model.

It doesn't need the breadth that a lot of these other models need, right? We don't have to go build a $500-billion data center in computing power. We don't have to fight for water and other things that people are all upset about. We can be very, very focused, but it's looking at evolutionary trends to understand why, over evolutionary time, certain animals have certain conserved regions of the genome that prevent things like cancer.

If you look at a protein like p53 in elephants, elephants get cancer at about a rate of 2% to 3%; humans are about 24% to 25%. They do that because that cancer suppression comes from an overexpression of p53, right? We have the largest dataset on elephants in the entire world. We actually have the largest dataset of multiple species of herpesviruses, because EEHV is a herpesvirus that kills elephants, right?

When you start to look at why certain species have invulnerabilities to certain disease states that affect human health care, we can track that evolutionary trend over time and even build, if you look at some of the prediction models out there, a prediction model that can be applicable not only to cancer evolution but also to things like bird flu and other things. What's really interesting is that, while AI is critical to what we're doing at Colossal, none of this would be possible without AI, and a lot of the stuff that we've had to build is bespoke. We're now even applying it to the next level of drug and therapeutic design and discovery.

Molly O'Shea

That's insane.

Ben Lamm

All using ancient genomes all the way through the most recent genomes, which is crazy.

10. How ancient DNA actually gets to the lab

Molly O'Shea

Okay, one thing, when we were walking through—I know this is kind of maybe a nerdy thing—but I was just totally blown away by even the supply chain of everything that goes into finding the cells for these things, how they extract DNA from samples that are thousands of years, sometimes millions of years old, that kind of thing. And then also the pigeon eggs that you have.

Ben Lamm

Yeah. Yeah. We have the pigeon colony, and we have a bunch of strange things. We have a chief animal officer. We have fresh pigeons that come from our avian facility. These are things I never thought I'd have because I come from mostly traditional SaaS and software. I never thought I'd have any of these roles. We have an incredible team that takes care of things like woolly mice, right? These are things that we didn't have.

But there is so much, and I think that's the value that we've built. We try to look at this from a vertical integration, first-principles perspective. We had to own the entire stack, right? So that's why, when we were looking at expanding our endangered species production, our biobanking and BioVault initiative, and our global network that we've been rolling out, buying ViaGen made a lot of sense, right?

When you look at animal cloning, for most people, it's dogs, cats, and horses. But there were 2 companies: ViaGen in the U.S. and a company in South Korea, so there were really 2. ViaGen had cloning efficiencies at 80%, where most people are at 2%, right? So it made sense for us to say, “Okay, we need to buy them and bolt them on” from a vertical integration perspective.

So much of the supply chain we either built, innovated, licensed, or bought, but you got a taste of it today. We had to build it; we put the entire thing under 1 roof. I think that cross-disciplinary function of allowing people to work from everything from animal ops to ancient DNA extraction and everything in the middle makes the products go faster and better.

Molly O'Shea

So we have to let our furry friends go.

Ben Lamm

I know. They only get so much time with us.

Molly O'Shea

They only get so much time. The rest, you have to pay for. I'm just kidding. [Laughter] But we'll say goodbye to the little woolly mice, and then we'll just continue after that.

11. The real stats behind Mass Extinction

So, to set the stage, you started this on the premise of extinction. So what are the stats? I know this is dark.

Ben Lamm

No, it's super dark. It's dark, but I think it's hopeful, right? I'm an eternal optimist. It's currently forecasted that we're going to lose up to 50% of all biodiversity in the next 25 years. That's dark. But that's why we have to do stuff, right?

Sometimes people get confused that we think de-extinction is a replacement for modern conservation. We do not think that. But the reality is, no matter how good conservation works, it just doesn't move at the speed at which we're eradicating species and changing the planet. We're doing that. That is happening.

For us, if you have a combination of a de-extinction toolkit that has lots of other ramifications, which we've talked about some, and you get governments to invest in a global, distributed biovault network, they're at least backing up things. At least we're starting to build a backup plan. And then, lastly, we open-source all of our technologies for conservation. Anybody can use any of our technologies for free for conservation.

There are always going to be bad actors, right? You can't prevent that. That's like when—I don't even remember, maybe a decade ago—San Francisco temporarily put a moratorium on investing in facial recognition because China was doing some bad stuff, isolating populations using facial recognition. That doesn't mean facial recognition is bad. That just means people are going to use it in bad ways, right?

But that doesn't mean that we shouldn't innovate the technologies for positive use cases, right? These technologies are very, very powerful, and people are going to do all kinds of bad things, probably, with them. But that doesn't mean that we shouldn't engineer them and make them so that people can do good with them. I'm an eternal optimist, so I believe that we, as a species, will ultimately do more good with them than bad.

So we're open-sourcing them to the conservation community for conservation purposes. If people use our technologies for nefarious reasons and not for conservation, then, yeah, we would probably step in and enforce that.

Molly O'Shea

Straight to jail.

Ben Lamm

I don't know if we have that power, but we'd give them a lot of legal feedback.

Molly O'Shea

No, that's really interesting. We were just talking when the woolly mice were here before you, and I forget her name. What's her name?

Ben Lamm

Oh, Katie.

Molly O'Shea

Oh, Katie. Yeah. So, I was talking with Katie, and she was telling me how she got here. I was like, "How long have you been here?" She said she's been here for 3 years. She was at a zoo first, then she was at a clinic, and then she came over here. She was like, "Well, the conservation and preservation side of things is completely broken. There's literally no movement. Nothing's going on there. It's boring."

Ben Lamm

Sometimes it's hard, and we had a lot of negative feedback on this at the beginning. It went from negative to neutral, and now it's becoming more and more positive. But the conservation community has historically been some of the most vocal critics of the work, because I think they viewed it early on as though we had positioned ourselves as a replacement for modern conservation, which we never did.

We're like, "No, no, no. You should do conservation work. Don't give us money." We always viewed this as net-new ideas, net-new money, net-new technology, and net-new awareness, right? Most people don't know that 20% of baby elephants die because of EEHV. People should know that. If you go talk to any of our elephant conservation partners, they'll tell you that their funding has gone up since Colossal was invented.

Molly O'Shea

Damn. I view it as a net positive, but in the early days, to her point, it did take some long conversations with that community, because that community is very stuck in its own ways. But if you spend time with that community and you ask them, "Are we, as a whole—as humanity as a whole—with current modern conservation techniques, winning the fight to save species?" they will all tell you no.

Ben Lamm

So, okay, we've got to do something different. We argue that 99% of people should keep doing what they are doing with conservation, and we're that 1% difference. But wouldn't you rather have a de-extinction toolkit and not need it than need a de-extinction toolkit and not have it?

Remember Star Trek, when the aliens came and they were like, "We don't have blue whales, and if we don't have the sound of a blue whale, we're going to destroy the planet"? Do you remember this? Absolutely. Old-school movie. They had to go back in time, capture a blue whale, and bring it to the future so the aliens didn't destroy us.

We don't have that exact issue currently. At least, I don't think there's a lot of UFO noise right now, so maybe they're looking for something. But ultimately, I would rather have this technology set and not need it, or at least use it in some of these interesting capacities that help individual species, inspire the next generation, and get people excited about science.

I'd rather do that and never need it for a mass-scale extinction event than have a mass-scale extinction event—which we know we're in right now, we know that's happening—and then not have these tools.

Molly O'Shea

So, in practice, are you going to be releasing any of these animals, like the—

Ben Lamm

In a couple phases. Obviously, you have to work very closely with governments, Indigenous people groups, and private landowners. For our extinct species, we do want to put them back into the wild with all these collaborations in place, where they help the ecosystem. The government's supportive, and the Indigenous people groups are supportive.

We want to do that for our gene drives and whatnot. That's also highly up to the government. Right now, we're educating the USDA, the intelligence community, the Department of War, and others on these technologies and how they can combat these issues domestically and abroad. But it is up to them. They have to give us the green light.

I did an interview about the screwworm, and it went viral. Then there were 20 articles about it, and there was feedback on Bluesky, of all places. I was surprised there was negative feedback on Bluesky—the echo chamber, or liberal Twitter, you know. The feedback was, "Well, Colossal doesn't have permits." Yes, we don't have permits, but this is a technology that, if it is permitted, can eradicate this problem.

In the screwworm example, they're spending $1.5 billion in taxes, and in 8 years they're going to slow or stop the problem. Our solution, which is already made, could eradicate the entire problem in every model that we've done in 6 to 7 months.

So, we could save a decade and billions of dollars for taxpayers, as well as spare the animals that are going to go through this painful death from the screwworm. If you're a beef person, the price of beef is going to stay low. If you're an animal welfare person, these animals are not going to be in pain from this terrible infectious disease that comes from the burrowing screwworm larvae. And if you're somewhat fiscally minded, we're going to save the taxpayers money.

These are those technologies. But once again, to put it back in the wild, we have to have the support of the government. Our goal for our de-extinct species, our genetically modified gene drives, and even cloning of endangered species is for all of that to go into the wild, but we have to have government, Indigenous, and global support.

12. Building this company with no background in Biology

Molly O'Shea

This is honestly just so crazy. It's also really cool because you come from a real tech software background. You're already very—if you've seen other labs, this probably looks most unlike any other lab you've seen.

Ben Lamm

No, I mean, it's beautiful. It's cinematic. It feels like a tech office.

Molly O'Shea

There's fun stuff going on in the background of it. It is very techy for a lab, for sure.

Ben Lamm

We look at this more as a product company and a tech company than a traditional biotech company. We're not an academic lab. We're not a think tank. We're not a biotech that's going to just work on 1 solution. We have to innovate across the entire spectrum of the pipeline, and I think that you feel it here.

There's a real sense of urgency toward the mission, which I think we have to have, given some of the stats we talked about.

Molly O'Shea

Yeah, so how did you construct the organization?

Ben Lamm

Having zero background in biology and biotech, I couldn't be more qualified to run this company.

But we look at it as a systems model. Extinction is a systems model. Genetic engineering, from taking a 73,000-year-old skull and going to puppies, is a systems model. Taking that kind of approach means asking the right questions and trying to fill in the right pieces.

What's great about this company, and is also hard about this company, is that there's not another one, right? There's not another de-extinction company. It's not like, "Here's your SaaS company roadmap," right?

The good news is that if we make mistakes, there aren't really other people to be judged against, because no one else had ever done it before. The bad news is that no one had ever done it before. We tried to take a very rudimentary, first-principles approach to building from the ground up. How do we build complete vertical integration into how we thought through the design of the business?

We've reorganized a couple of times internally, and I feel like we finally got the right momentum as a company. I think you're starting to see that with more and more innovations that come out of the company.

Molly O'Shea

What does that composition look like? Lab research?

Ben Lamm

It's mostly scientists. We have 260-plus people, plus 17 academic partners, plus 80 folks in academic labs that we also fund, and about 95 advisers.

Molly O'Shea

Oh, my God.

Ben Lamm

I know. But they're tiered. We have scientific advisers, Indigenous advisers, executive business advisers, and youth advisers, right?

Most people don't realize this. Everyone talks about our problems and how the youth are going to inherit the problems. They're also going to inherit our solutions to some of these problems. When we're solving these problems, if we're solving them in dumb ways, like I think a lot of the air-capture systems, direct-air-capture carbon systems, and a lot of other ways that we're trying to solve climate are dumb.

If we invest $1 trillion in that infrastructure globally and hand it to our kids, our kids are going to have to contend with the tech debt that comes with that. We've tried to think through how to make a solution that not only we're proud of, but that our next generation is proud of, too.

That's why having a youth advisory board is really helpful. Getting their feedback is as important as the feedback from our Indigenous board or our scientific board. So, it sounds like a lot of people, but we have different groups that manage each one of those external folks.

Molly O'Shea

It also seems like you guys are really popular with kids either way.

Ben Lamm

Every decision we make, if you go to the highest level, is about trying to create value for our investors, impact for the world, and inspiration. For us—and we told our investors this from day 1—inspiration needs to be as important as value creation, and you need to be on board with that. If we do the greatest thing in the world that nobody knows about, and kids don't get excited about science, then we think we failed.

We really try to put a heavy emphasis on kids and education. I have this conversation with the scientific community a lot, including in some of the scientific journals: Kids don't read Nature, Science, and Cell, right? The ones who do—I don't know; they should work here. But the kids who read those journals are already committed to science, which would be incredible.

Most people are like, "We're competing with pop culture for the latest celebrity trend." You have to be able to communicate really hard things like CRISPR and some of these genome-engineering tools, as well as their impact and positivity in the world and what they're doing today. You have to do it in 20 seconds, and you have to do it on Instagram.

Molly O'Shea

That's real, right? Because that's where people are—that's where the next generation is. That's how they communicate, right? What's our Snapchat strategy? Those are the things we think about.

13. Choosing their earliest backers

Well, we should talk about your funding history, because I can imagine that has evolved the story and the business model—the believers versus the ones that are backing up the truck now. It's probably very different.

Ben Lamm

Yeah, sure.

Molly O'Shea

I can imagine that has evolved the story and the business model—the believers versus the ones that are backing up the truck now. It's probably very different.

Ben Lamm

In the early days, we were very thoughtful. We wanted long-term, technology-focused investors—people who could look at this and say, "What is the event horizon? 10 years, 20 years, 50 years out?" We were not looking for investors who were saying, "We want a fund return in 4 to 5 years in Fund X," right? Those just weren't for us.

We have some of those, but they were not our primary focus. Then we wanted a percentage of impact investors—people for whom part of their internal KPI system is tracking positive impact. We really tried to find the right balance, and I think we did a really good job.

I think most people would have said, "Oh, you should call Masa or SoftBank out of the gate," right? I think that's how most people think about a business like this. But we haven't, right? We didn't. We're big fans of what he's done, but some of those types of funds we didn't go after.

We said, "Okay, let's go to very thoughtful businesspeople. Let's go to people like Jim Breyer. Let's go to people like Thomas Tull and Mark Walter"—people who have built these legacy, large infrastructure plays and have done things in education, entertainment, science, and technology. People who were early backers in the internet and quantum, and who understand what whole new economies and systems can come from getting the entire pipeline right.

I think we were very thoughtful about that. It's funny: I think we've completely mispriced every single round of capital, because every single round of capital has been more than 2× oversubscribed. What I hear from that is, "We're cheap." We're a cheap date, and we should raise our rates on capital. Maybe we'll do that in the future.

Molly O'Shea

Don't sell yourself short.

Ben Lamm

I think—yeah. But every round has been massively oversubscribed, so it makes me think that people are not just excited and see the vision and the impact, but they also think they've got a good deal.

Molly O'Shea

But this is not your first rodeo. I mean, you've had a successful exit.

Ben Lamm

Yeah. I've been very fortunate to work with much smarter people than me to build a handful of businesses that have had successful, profitable exits. I do think that helps. I think that helped in the early days, right?

In the early days, our original deck was: "We have no scientists, we have no partnership with Harvard, we have no technologies, and we're a handful of software and hardware people who have no background in biology. George Church thinks he can make a woolly mammoth, and we're pretty sure that's worth something."

That was the original deck, and it was pretty bad. I'm being honest: I would've passed on it. I talked to an investor who passed in the early days, who now has a very big fund and wants to get involved, and he was like, "I just can't believe I passed on this." I was like, "I would've passed on this. In all reality, I would've passed on this."

Molly O'Shea

Yeah. So, how did you guys prove them all wrong?

Ben Lamm

I think trust. I think it's easy to raise capital when you have trust, and I think trust is built by setting and managing expectations. We've done a really good job with our investor base, hopefully with the world, and also with our board, of setting and delivering on expectations.

I think we've had these surprise-and-delight moments. The dire wolves were definitely a surprise-and-delight moment. Delivering on our roadmap—we've been very consistent in our delivery, and we've been ahead. I think we've also done a really good job of exceeding expectations of what's possible.

We were told that if, in 5 years, we were doing 5 to 7 edits, we'd be great. We're now doing 100. You saw we're doing hundreds of edits. We haven't done this yet, but we're now pushing a new construct that we've designed and a new delivery mechanism that we think will allow us to do thousands of edits at once.

These are things that 3 years ago sounded impossible. A year ago, they still sounded impossible. I think we're consistently showing that. When you build that trust, I think it's very easy for people to continue to deliver or to invest.

I mean, we saw some lasers back there. Yeah, there are some lasers, right? The laser thing is pretty cool. But eventually, even that—that was in our somatic cell nuclear transfer, or cloning, lab—but that entire embryology process will eventually all be automated, right?

We've got the best embryologists doing the same thing every single day in multiple different clades of animals. In that screen that you saw, that's doing full-time screen recording.

We're looking at the position of the laser. We're looking at the position of the oocyte. We're looking at how much DNA is extracted. We had to build that entire system. I don't know if they told you that on the tour. That's all custom, so we had to build and innovate all of that hardware. In the future, that whole process will be automated with robotics.

Molly O'Shea

So, do you get a report at the end of the day or at the end of the month? How do you learn and train off of that?

Ben Lamm

On that data, it's highly visual data. It's all screen capture and computer vision from an input and capture perspective. We track efficiencies and cloning rates, and we track all of that in spreadsheets.

Now, thanks to some of the next-gen applications of AI, we can do that. In the early days, things like OpenAI, Claude, and others weren't super helpful to our company, because it turns out that Opus doesn't do ancestral-state reconstruction of a genome, and it doesn't build comparative-genomics models. We had to go build all of that.

Which I think was good because we had to build out an AI team and think through some pretty hard problems. But now we're connecting existing systems. Most labs don't use things like Jira, so I think the hardest thing we've done is reprogram—not stem cells, but scientists—to work in things like Jira and Smartsheet, traditional software tools.

We're connecting those to the lab notebooks and some of our proprietary systems, all through an AI layer. The visibility that we can give our mid-level and senior management on the science teams of what's happening in the lab in near real time, through the aggregation of AI across systems, is really powerful. Now we're implementing some of these existing enterprise AI systems at scale, and it's really, really helping.

Molly O'Shea

So, between that and the labs, and how everything is designed here in this secret location, how did you get—I mean, you have a very distinctive style here. How did you develop that style and the branding around it?

Ben Lamm

We wanted to make—once again, we couldn't be more underqualified—we wanted to make science cool, fun, and engaging. When we set out to do the task of getting rid of extinction, we thought it was a big problem, so we thought Colossal was a good name because it's a pretty big problem that we're trying to solve.

At the same time, we're also working with cells, which we thought was funny: We're working with the smallest things, but hopefully they're successful enough to make really big things. So we're kind of planning success, right, with the name and stuff. That's why we came up with the name.

But then we had this idea: If you're going to go back to the Bill Nye old-school models of science and excitement, where you're putting in the red food coloring and shit's exploding in the volcano, versus today, where it's only spelling bee champions and kids inventing nuclear fusion, how do you go back to the stuff I could do in the '80s and '90s?

That's old-school MTV, back before it was 16 and Pregnant, when it was TRL. How do you go back to the TRL days of MTV and mash that up with the robustness, thoughtfulness, and scientific rigor of Harvard? Harvard is boring and stuffy, so how do you take Harvard meets MTV? That was our thesis from day 1, and I think we nailed it. I think the colors and the attitude really work.

Molly O'Shea

I mean, it's sick. When we walked in—

Ben Lamm

But if I said to you randomly, if you had not been here or seen anything, “Harvard meets MTV,” you'd be like, “That's just dumb.” But now that I say “Harvard meets MTV,” with everything you've seen, you're like, “That actually describes exactly what you guys have built.”

I'm very proud of that because we spend a lot of time on it. We want to evoke our brand in the messaging. We don't want to just say, “We have happy hours once a month and foosball tables.” We don't have foosball tables; they're annoying and loud. That's why you see the murals and everything in there. We want to constantly remind not just the people who come here, but our staff.

We have this unfair advantage in recruiting because you get to work on things like woolly mammoth cells and dodos versus yeast in an academic lab. But also, after you work in this lab, go try working in another lab. Go work back in academia, where you're underfunded, everything is massively politicized and massively competitive, and your labs are held up by pizza boxes. Go work in academia after you work here. You just don't see that.

Molly O'Shea

I mean, we are technically—well, I can't say where we are—but there are lots of medical buildings around us.

Ben Lamm

Yeah. They don't feel like this, though.

Molly O'Shea

No, I would imagine they don't. We accidentally walked into a few.

Ben Lamm

Yeah.

Molly O'Shea

Because it's really hard to find.

Ben Lamm

Yeah, yeah. This is good. Great. That's the best thing I learned today.

14. Why they refuse to work on Humans

Molly O'Shea

Yeah. But I'm really curious. Okay, here's a hard question.

Ben Lamm

I love hard questions.

Molly O'Shea

What's on the no-go list? What can you not make? I listened to a few podcasts, and one of them was like—

Ben Lamm

Ironically, the T-shirt that I'm wearing is what we can't do. This is Gigantopithecus, which was not King Kong, but an extinct ape. It was a giant.

We will not work on anything related to humans. Our technologies can be applied to humans, and we can spin them out and license them, but we won't do the human work here. I made the joke before, but we don't want to have Colossal launch a hair solution and then people say, “Is that mammoth that people are putting on us?” We never wanted that.

There are already fringe groups of people who have some crazy conspiracy ideas about us. I don't want to encourage the idea that we're a secret government lab. I mean, the list goes on.

Molly O'Shea

A government lab would be like this. Cool.

Ben Lamm

No, right. But that's part of the cover-up. We have all kinds of weird things. We actually had a very critical group from this one New York-based publication that is just weird. They like to be critical about lots of things.

They were here, and at the end of it they asked, “Do you secretly have a mammoth that you're not telling us about?” I said, “No. Why would we do that?” So there are all kinds of weird things.

We won't work on humans here because we've been asked the Neanderthal question. We won't work on nonhuman primates in vivo, either. Gigantopithecus would be amazing to see, but we're not going to do that.

Molly O'Shea

You did this crazy interview with Ashley Vance. Has he come in here yet?

Ben Lamm

No, he hasn't been here yet. I've done his podcast. Weird. It's crazy that you just said this. I think I was his first podcast when he left. I think I was the first episode, or maybe the first remote.

Molly O'Shea

Really?

Ben Lamm

He literally messaged me about a week ago, and we're testing—

Molly O'Shea

In his studio?

Ben Lamm

It was a remote, but he literally messaged me about a week ago, and we're testing something. He's great. I didn't know him before we did his podcast, but he was awesome. We just reconnected literally in the last week.

Molly O'Shea

He has crazy—I mean, he's seen some crazy stuff. You went with George Church to, you know, whatever land, and you've seen drawers with lots of stuff in them, but he went to Russia or Serbia or something. I don't know where it was. It was some cold place over there, and there was this mad scientist dude who was, I guess, a chill guy, but he had human heads in a cold locker and all this stuff. I'm like, “Ashley, you were there.”

Ben Lamm

Yeah.

Molly O'Shea

What?

Ben Lamm

He's like, “Yeah, that was the craziest interview I ever did.” I'm like, “We'll work to top it next time he's here.” Or he hasn't been here, but when he comes—yeah, he's great.

Molly O'Shea

He's great.

Ben Lamm

Yeah, he's great. There is definitely some weird stuff.

But synthetic biology—I don't think this is what people realize. The intersection of AI and compute, eventually quantum, and synthetic biology will transform everything. George and I have been asked this question. We were on some podcast—maybe Adam Draper's podcast—where he asked, “If you and George could do one thing, what would it be?”

We both talked about how we have this weird idea that eventually we will be able to program trees. Can you build a redwood that actually grows in the form of a house? We went down this really weird, mushroomy, hippie path, and I think it was even too weird for Adam Draper. He was like, “Okay, mammoth.”

I think that's going to be the power of synthetic biology: the idea that we can program life in whatever image we want is pretty amazing. We're advancing it, I think, further than anyone, but at the same time, we haven't even scratched the surface of what's going to be possible.

Molly O'Shea

Any megalodons?

Ben Lamm

This just shows how out of the world it is. Dinosaurs are request 1. Megalodons are request 2.

Molly O'Shea

Well, you have a megalodon room.

Ben Lamm

I do. Megalodon—but that's because it's—

Molly O'Shea

It's really cool.

Ben Lamm

It's a really cool room, but it's a fish tank, right? It's a fishbowl, so you have to do something thematically. There is no megalodon DNA. If there was, it would be terrible to make. The ocean is scary enough, but we do get requests for megalodon quite a bit. We're not working on McDonald's.

Molly O'Shea

Okay.

Ben Lamm

There's no secret U.S. Navy–Anduril mashup for megalodon.

15. Are they secretly working on Aliens?

Molly O'Shea

They don't ask you to do your work on aliens?

Ben Lamm

No, no. That's another thing that we get. I've been weirdly, tangentially connected to the UAP crowd for a long time. Previously, I had a satellite company and did some imaging work for Army Space and some other things at a previous company. I'm on the UAP scientific advisory board for AARO, so I understand why people draw the conclusion.

Molly O'Shea

It's not as reasonable. People think that part of one of the other conspiracies is—

Ben Lamm

Like, the advancements in genome engineering have come from us studying aliens, which is just not the case. That's just crazy talk.

Molly O'Shea

I'm glad you clarified that today.

Ben Lamm

Yeah, it's crazy talk. We could spend an hour just on weird Reddit conspiracies around Colossal.

Molly O'Shea

That's fun.

Ben Lamm

It's fun. We should do that. Most fun.

Molly O'Shea

Okay. Well, Ben, that leaves us. We're out of time.

Ben Lamm

Thank you so much. This was so much fun. The tour was insane.

Molly O'Shea

Yeah, good. I'm glad you came.

Ben Lamm

I was actually a little concerned walking from the tour into here because my mind just exploded.

Molly O'Shea

Yeah, good. I love that. That's awesome.

Ben Lamm

So, thank you.

Molly O'Shea

I'm glad you came. So—

Ben Lamm

Cool.